Trial · NCT01253980
Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
NCT01253980, Not applicable, Completed, University of Cape Town; results first posted 2013-06-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children. Trials, record NCT01253980. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01253980
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
- NCT number
- NCT01253980
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 74 participants, actual
- Lead sponsor
- University of Cape Town
- Conditions
- Kerosene Pneumonitis
- Interventions
- Amoxicillin, Placebo
- First posted
- 2010-12-06
- Last updated
- 2015-11-09
- Results first posted
- 2013-06-26
- Limitations and caveats
Early termination leading to small number of participants. Some patients did not attend follow-up and were only contacted by phone, therefore clinical data not available for all participants at follow-up.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Failure | At routine follow-up 3 and 5 days post-ingestion or earlier if necessary | A treatment failure was a patient who at any time deteriorated necessitating a change to the treatment regimen. This was determined by assessing reported symptoms (cough, shortness of breath, wheeze and fever) and comparing clinical signs (respiratory rate, oxygen saturation, wheeze, flaring, grunting, recessions, crepitations, temperature, mental status) to signs at presentation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Treatment Failure | At routine follow-up 3 and 5 days post-ingestion or earlier if necessary | per protocol | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Treatment Failure | Placebo | 3 | 95% Confidence Interval 3 to 22 | participants | |
| Treatment Failure | Amoxicillin | 2 | 95% Confidence Interval 1 to 17 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 35 | |
| Overall Study | STARTED | Amoxicillin | 39 | |
| Overall Study | COMPLETED | Placebo | 35 | |
| Overall Study | COMPLETED | Amoxicillin | 39 | |
| Overall Study | NOT COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Amoxicillin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Amoxicillin | ||
| Total, other adverse events | Placebo | 0 | 35 |
| Total, other adverse events | Amoxicillin | 0 | 39 |
| Total, serious adverse events | Placebo | 0 | 35 |
| Total, serious adverse events | Amoxicillin | 0 | 39 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26114347 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Amoxicillin vs Placebo: Treatment Failure | Trial comparisons |
| Amoxicillin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01253980
GET https://conductscience.org/api/trials/v1/NCT01253980/registered